Technical Analysis for XBIO - Xenetic Biosciences, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 3.93 | 1.95% | 0.08 |
Earnings due: May 9
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 200 DMA | Bullish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| 20 DMA Resistance | Bearish | 1.95% | |
| 50 DMA Resistance | Bearish | 1.95% | |
| Fell Below 200 DMA | Bearish | 1.95% | |
| Gapped Up | Strength | 1.95% | |
| Fell Below 20 DMA | Bearish | -0.88% | |
| Fell Below 50 DMA | Bearish | -0.88% |
| Alert | Time |
|---|---|
| Possible NR7 | about 16 hours ago |
| Possible Inside Day | about 16 hours ago |
| 60 Minute Opening Range Breakout | about 20 hours ago |
| Rose Above 200 DMA | about 20 hours ago |
| Up 1% | about 20 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/09/2024
Xenetic Biosciences, Inc. Description
Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company's platform technologies that enables the creation of drug therapies primarily for orphan indications. The Company's technologies include PolyXen, Virexxa, OncoHist and ImuXen. The Company is focused primarily on developing its lead product candidates, including ErepoXen, Virexxa and OncoHist, and PolyXen technology. The Company's lead product candidate ErepoXen, a polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease, and Food and Drug Administration (FDA) orphan designated oncology therapeutics Virexxa and OncoHist for the treatment of progesterone receptor negative endometrial cancer and refractory Acute Myeloid Leukemia, respectively. It is also developing PSA-FVIII.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmacy Pharmaceutical Products FDA Acute Myeloid Leukemia Kidney Disease Dialysis Anemia Chronic Kidney Disease Drug Therapies Platform Technologies Endometrial Cancer Refractory Acute Myeloid Leukemia Erythropoietin Growth Factors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.97 |
| 52 Week Low | 2.55 |
| Average Volume | 6,241 |
| 200-Day Moving Average | 3.89 |
| 50-Day Moving Average | 4.14 |
| 20-Day Moving Average | 4.04 |
| 10-Day Moving Average | 4.02 |
| Average True Range | 0.31 |
| RSI (14) | 47.09 |
| ADX | 11.99 |
| +DI | 19.05 |
| -DI | 12.98 |
| Chandelier Exit (Long, 3 ATRs) | 3.79 |
| Chandelier Exit (Short, 3 ATRs) | 4.69 |
| Upper Bollinger Bands | 4.42 |
| Lower Bollinger Band | 3.65 |
| Percent B (%b) | 0.35 |
| BandWidth | 19.09 |
| MACD Line | -0.05 |
| MACD Signal Line | -0.04 |
| MACD Histogram | -0.0142 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.93 | ||||
| Resistance 3 (R3) | 3.93 | 3.93 | 3.93 | ||
| Resistance 2 (R2) | 3.93 | 3.93 | 3.93 | 3.93 | |
| Resistance 1 (R1) | 3.93 | 3.93 | 3.93 | 3.93 | 3.93 |
| Pivot Point | 3.92 | 3.92 | 3.92 | 3.92 | 3.92 |
| Support 1 (S1) | 3.92 | 3.92 | 3.92 | 3.92 | 3.92 |
| Support 2 (S2) | 3.92 | 3.92 | 3.92 | 3.92 | |
| Support 3 (S3) | 3.92 | 3.92 | 3.92 | ||
| Support 4 (S4) | 3.92 |
